** Hikma rises as much as 5 pct to 2520 pence afterco maintains FY guidance, making them the second highestFTSE-100 gainers
** Shares rise to highest in almost 6 months, with 70 pct ofavg 30-day volumes going through in first 3 hours
** Stock is also number 3 gainer on Europe's benchmarkSTOXX-600 index
** Hikma's H1 revenue falls 4 pct, but co keeps FY revenuegrowth forecast of around 6 pct in constant currency terms
** Jefferies analysts say H1 was irrelevant given stronggrowth prospects from 2016 and they expect market to look beyondsecond-half-weighted year to future value drivers
** Co bought Boehringer Ingleheim's specialty generics drugsbusiness in the U.S. for $2.65 bln last month.